Across samples from patients with T-ALL, either wild-type and mutant for DNMT3A, genetic inhibition of BIRC5 did not alter overall time to morbidity (Figure 7E) or disease burden compared with AAVS1-targeted cells (supplemental Figure 8G). This evidence concerns the gene BIRC5 and acute lymphoblastic leukemia.